百诚医药

百诚医药 (Hangzhou Bio-Sincerity Pharma-Tech) is a comprehensive pharmaceutical research and development platform based in Hangzhou, China. Founded in 2011 and listed on the Shenzhen Stock Exchange in 2021, the company provides full-service contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, covering pharmaceutical research, formulation development, clinical trials, and bioequivalence studies. In addition to its service offerings, 百诚医药 actively develops its own proprietary pipeline of chemical category 1 innovative small molecule drugs. Its lead candidate, BIOS-0618, is a histamine H3 receptor antagonist currently in Phase 2 clinical development for indications such as neuropathic pain and obstructive sleep apnea-induced excessive daytime sleepiness. The company also utilizes AI-driven models and bioship technologies to accelerate drug discovery across neurological, autoimmune, and oncology therapeutic areas.